PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Chlormidazole→

Chlormidazole PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
3689-76-7
Molecular formula
C15H13ClN2
Molecular weight
256.73 g/mol
Drug class
Topical benzimidazole antifungalearly azole antimycotic
Mechanism of action
An early benzimidazole azole antifungal. The azole class inhibits fungal lanosterol 14-alpha-demethylase (CYP51), impairing ergosterol biosynthesis and compromising fungal cell-membrane integrity. The exact enzyme target was not established in the original chlormidazole development studies.
Indications / reported uses
  • Historically marketed as 5% topical cream or tincture for dermatomycoses and Candida infections; products appear to have been withdrawn or are no longer widely available. This is a historical pharmacology entry, not a current routine treatment.

Sources: https://www.mdpi.com/2079-6382/15/11/1043 · https://pubmed.ncbi.nlm.nih.gov/945306/ · https://www.aspergillus.org.uk/timeline_date/development-of-chlormidazole/ · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Chlormidazole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Chlormidazole Permitted Daily Exposure (PDE) report (the Chlormidazole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Chlormidazole Occupational Exposure Limit (OEL) report (the Chlormidazole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.